Drugs / MitoQ
MitoQ
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05605548 | Feb 2023 → Jul 2024 | chronic obstructive pulmonary disease | Virginia Commonwealth University | Terminated | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05381454 | Apr 2022 → May 2023 | COVID-19, viral respiratory tract infection | University of California, Los Angeles | Completed | Met primary |
| Phase 26 trials | ||||||
| Phase 2 | NCT06027554 | Oct 2024 → Mar 2027 expected | cognitive impairment with or without cerebellar ataxia | UConn Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06429059 | Jun 2024 → May 2025 | amyotrophic lateral sclerosis | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT06351683 | Apr 2024 → Apr 2026 | overactive bladder | Iman Al-Naggar, PhD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01167088 | Nov 2010 → Jun 2011 | NAFLD1 | Antipodean Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00433108 | Mar → Nov 2007 | chronic hepatitis C virus infection | Antipodean Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00329056 | May 2006 → Nov 2007 | Parkinson disease | Antipodean Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06191965 | Jun 2024 → Jan 2027 expected | mitochondrial disease, schizophrenia | Mclean Hospital | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05146843 | Jun → Nov 2022 | breast cancer | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| — | NCT04558190 | Sep 2020 → Nov 2021 | — | University of Copenhagen | Completed | No outcome recorded |
| — | NCT02597023 | Sep 2015 → Dec 2017 | — | University of Colorado, Boulder | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT04267926 Comparator | Apr 2020 → Oct 2024 | multiple sclerosis | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT03166800 Comparator | Sep 2018 → Jan 2019 | multiple sclerosis | Oregon Health and Science University | Terminated | No outcome recorded Stop: Business |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MitoQ | “Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.” NCT06027554 ↗11“Oral administration of MitoQ capsules” NCT04558190 ↗ “Mitoquinone mesylate tablets (MitoQ)” NCT01167088 ↗ “Mitoquinone mesylate (MitoQ)” NCT00433108 ↗ |
| Known as | Mito-MES | “the mitochondrial antioxidant mitoquinone/mitoquinol mesylate (Mito-MES), a dietary supplement” PMID 38471990 ↗ Mar 2024 |
| Known as | mitoquinol mesylate | “MitoQ (mitoquinol mesylate)” NCT06351683 ↗ |
| Known as | Mitoquinone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05146843 ↗ |
| Known as | Mitoquinone mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229093 ↗ |
| Known as | Mitoquinone mesylate | “Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans” PMID 38471990 ↗ Mar 2024 |
| Known as | Mitoquinone methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229093 ↗ |
| Known as | mitoquinone/mitoquinol mesylate | “the mitochondrial antioxidant mitoquinone/mitoquinol mesylate (Mito-MES), a dietary supplement” PMID 38471990 ↗ Mar 2024 |
| Modality | Small molecule | — CHEMBL1229093 ↗ |
| Route | Oral | “we investigated the effect of oral mitoquinone on serum aminotransferases and HCV RNA levels” PMID 20492507 ↗ May 2010 |